Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas. PMID: 36680181
A Current Update on Human Papillomavirus-Associated Head and Neck Cancers. PMID: 31600915
Integrated genomic and molecular characterization of cervical cancer. PMID: 36214947
Detection of HPV16 viral load in L2 gene as a related predictor of cervical cancer among women in Dhi-Qar province by qRT-PCR. PMID: 36750540
Retraction Note: Detection of HPV16 viral load in L2 gene as a related predictor of cervical cancer among women in Dhi-Qar province by qRT-PCR. PMID: 25972404
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies. PMID: 26925750
HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer. PMID: 23762404
Differential expression of HPV16 L2 gene in cervical cancers harboring episomal HPV16 genomes: influence of synonymous and non-coding region variations. PMID: 32510304
Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens. PMID: 35763643
Human Papillomavirus Type 16 L2 Gene Sequence Variation Analysis in Indonesian Cervical Cancer Specimens. PMID: 29207600
Host cell transcriptome modification upon exogenous HPV16 L2 protein expression. PMID: 22154072
The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic. PMID: 23689062
L2, the minor capsid protein of papillomavirus. PMID: 24928042
The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network. PMID: 35458534
Human Papillomavirus L2 Capsid Protein Stabilizes γ-Secretase during Viral Infection. PMID: 23335178
HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. PMID: 34960729
HPV16 Entry into Epithelial Cells: Running a Gauntlet. PMID: 33802456
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. PMID: 35891458
HPV16 Induces Formation of Virus-p62-PML Hybrid Bodies to Enable Infection. PMID: 33568731
High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility. PMID: 27889616
Developments in L2-based human papillomavirus (HPV) vaccines. PMID: 27122588
Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins. PMID: 19860897
Role of L2 cysteines in papillomavirus infection and neutralization. PMID: 27654294
The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis. PMID: 35193933
ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. PMID: 34516991
Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model. PMID: 23388722
The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs. PMID: 28056100
Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PMID: 17980618
Transient expression of HPV16 E7 peptide (aa 44-60) and HPV16 L2 peptide (aa 108-120) on chimeric potyvirus-like particles using Potato virus X-based vector. PMID: 17239496
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. PMID: 22761884
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PMID: 24444361
An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16. PMID: 14505907
Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. PMID: 26569287
Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection. PMID: 12560332
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. PMID: 20684966
Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody. PMID: 34740725
A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant. PMID: 31743367
Glutathione contributes to efficient post-Golgi trafficking of incoming HPV16 genome. PMID: 35608352
Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum. PMID: 17010405
Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. PMID: 21346798
Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PMID: 33238224
Genetic signatures for lineage/sublineage classification of HPV16, 18, 52 and 58 variants. PMID: 19214230
Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PMID: 12610128
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. PMID: 17150135
Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. PMID: 10712890
Human papillomavirus vaccines. PMID: 18508629
HPV-16 RNA processing. PMID: 27518844
Human Papillomavirus Type 16 L2 DNA Methylation in Exfoliated Cervical Cells From College-Age Women. PMID: 36263027
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development. PMID: 22927980
The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PMID: 29212932
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. PMID: 26362430
Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. PMID: 28463988
Translocation of the papillomavirus L2/vDNA complex across the limiting membrane requires the onset of mitosis. PMID: 36815785
Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16. PMID: 27398412
Involvement of Nucleophosmin (NPM1/B23) in Assembly of Infectious HPV16 Capsids. PMID: 15507604
The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. PMID: 11158207
Papillomavirus-like particle vaccines. PMID: 29207511
Subcellular Trafficking of the Papillomavirus Genome during Initial Infection: The Remarkable Abilities of Minor Capsid Protein L2. PMID: 30996086
Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry. PMID: 20334659
Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. PMID: 11287582
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation. PMID: 30926288
Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer. PMID: 19368776
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. PMID: 27725301
Genomic diversity and phylogenetic relationships of human papillomavirus 16 (HPV16) in Nepal. PMID: 23383218
Optimization of multimeric human papillomavirus L2 vaccines. PMID: 30946955
The endocytic trafficking pathway of oncogenic papillomaviruses. PMID: 29914845
Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. PMID: 22351779
Influence of physiologic folate deficiency on human papillomavirus type 16 (HPV16)-harboring human keratinocytes in vitro and in vivo. PMID: 24662712
A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. PMID: 18367526
Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2., PMID:38022617
Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope., PMID:37798448
Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas., PMID:36680181
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545
Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women., PMID:35552511
Dissolving Microneedle Delivery of a Prophylactic HPV Vaccine., PMID:35139303
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates., PMID:33802456
Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433
Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485
Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963
Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens., PMID:32510304
Production and Preliminary In Vivo Evaluations of a Novel in silico-designed L2-based Potential HPV Vaccine., PMID:31729940
Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity., PMID:31147274
Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry., PMID:30996086
Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer., PMID:30926288
VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris., PMID:30091403
Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses., PMID:29914845
A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice., PMID:29854852
Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus., PMID:29743371
Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice., PMID:29683766
Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles., PMID:29269879
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses., PMID:29212932
High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16., PMID:29211035
Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types., PMID:28968993
Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies., PMID:28855937
Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes., PMID:28778613
Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies., PMID:28691664
Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process., PMID:28566382
A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines., PMID:28118086
Developments in L2-based human papillomavirus (HPV) vaccines., PMID:27889616
Comparison of human papillomavirus type 16 replication in tonsil and foreskin epithelia., PMID:27639574
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles., PMID:27147749
Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes., PMID:27113165
A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo., PMID:26855722
Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells., PMID:26853456
Humoral Immune Response Against Human Papillomavirus as Source of Biomarkers for the Prediction and Detection of Cervical Cancer., PMID:26780189
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes., PMID:26382603
Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach., PMID:26362430
Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine., PMID:26170394
Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination., PMID:26113972
Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2., PMID:26003490
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies., PMID:25972404
Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody., PMID:25905781
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types., PMID:25790098
Amino acid motifs in both the major and minor capsid proteins of HPV51 impact antigenicity and infectivity., PMID:25770119
Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer., PMID:25560237
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions., PMID:24999962
Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing., PMID:24962748
The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine., PMID:24917327
For research use only. Not for human or drug use.
